{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T11:26:27Z","timestamp":1775647587246,"version":"3.50.1"},"reference-count":56,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T00:00:00Z","timestamp":1631145600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:sec><jats:title>Aim<\/jats:title><jats:p>This study aimed to evaluate the association between opioid\u2010related deaths and persistent opioid utilisation in the United Kingdom (UK).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This nested case\u2010control study used the UK Clinical Practice Research Datalink, linking the Office for National Statistics death registration. Adult opioid users with recorded opioid\u2010related death between 2000 and 2015 were included and matched to four opioid users (controls) based on a disease risk score. Persistent opioid utilisation (opioid prescriptions \u22653 quarters\/year and oral morphine equivalent dose \u22654500\u2009mg\/year) and psychotropic prescriptions were identified annually during the three patient\u2010years before the date of opioid\u2010related death. Conditional logistic regression was used to assess the association between persistent opioid utilisation and opioid\u2010related death, and the results were reported as adjusted odds ratios (aOR) and 95% confidence intervals (95% CI).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of the 902\u2009149 opioid users, 230 opioid\u2010related deaths (cases) and 920 controls were identified. Persistent opioid utilisation was significantly associated with an increased risk of opioid\u2010related deaths (aOR 1.9, 95% CI 1.2, 2.9) when persistent opioid utilisation was defined by both annual dose and number of quarters. Concurrent prescription of opioids and tricyclic antidepressants (aOR 2.0, 95% CI 1.2, 3.5) or higher dose of benzodiazepine (aOR 6.5, 95% CI 4.0, 10.4) or gabapentinoids (aOR 6.2, 95% CI 2.9, 13.5) were associated with opioid\u2010related death.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Persistent opioid prescribing and concurrent prescribing of psychotropics were associated with a higher risk of opioid\u2010related death and should be avoided in clinical practice. An evidence\u2010based indicator to monitor the safety of prescribed opioids during opioid deprescribing is needed.<\/jats:p><\/jats:sec>","DOI":"10.1111\/bcp.15028","type":"journal-article","created":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T21:44:06Z","timestamp":1628545446000},"page":"798-809","source":"Crossref","is-referenced-by-count":21,"title":["Association between opioid\u2010related deaths and persistent opioid prescribing in primary care in England: A nested case\u2010control study"],"prefix":"10.1111","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9491-0421","authenticated-orcid":false,"given":"Teng\u2010Chou","family":"Chen","sequence":"first","affiliation":[{"name":"Centre for Pharmacoepidemiology and Drug Safety, Division of Pharmacy and Optometry, School of Health Sciences, Faculty of Biology, Medicine and Health University of Manchester, Manchester Academic Health Science Centre"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger David","family":"Knaggs","sequence":"additional","affiliation":[{"name":"Division of Pharmacy Practice and Policy, School of Pharmacy University of Nottingham  Nottingham UK"},{"name":"Primary Integrated Community Solutions, Nottingham Business Park  Nottingham UK"},{"name":"Pain Centre Versus Arthritis University of Nottingham  Nottingham UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li\u2010Chia","family":"Chen","sequence":"additional","affiliation":[{"name":"Centre for Pharmacoepidemiology and Drug Safety, Division of Pharmacy and Optometry, School of Health Sciences, Faculty of Biology, Medicine and Health University of Manchester, Manchester Academic Health Science Centre"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,9,9]]},"reference":[{"key":"e_1_2_11_2_1","unstructured":"Centers for Disease Control and Prevention.Vital signs: overdoses of prescription opioid pain relievers\u2010United States 1999\u20102008. Moridity and Mortality Weekly Report;2011. Available from:https:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/mm6043a4.htm[accessed July 2020]."},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/injuryprev-2015-041604"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/AJP.0b013e318169d03b"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.1464"},{"key":"e_1_2_11_6_1","unstructured":"Office for National Statistics.Deaths related to drug poisoning in England and Wales 2017 registrations;2018. Available from:https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/birthsdeathsandmarriages\/deaths\/bulletins\/deathsrelatedtodrugpoisoninginenglandandwales\/2017registrations[accessed July 2020]."},{"key":"e_1_2_11_7_1","unstructured":"Advisory Council on the Misuse of Drugs.Reducing opioid\u2010related deaths in the UK. December2016. Available from:https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/576560\/ACMD-Drug-Related-Deaths-Report-161212.pdf[accessed July 2020]."},{"key":"e_1_2_11_8_1","first-page":"29","article-title":"Drug\u2010related mortality: methods and trends","volume":"93","author":"Christophersen O","year":"1998","journal-title":"Popul Trends"},{"key":"e_1_2_11_9_1","unstructured":"Office for National Statistics.Report: deaths related to drug poisoning: results for England and Wales 1993 to 2000. Health Stat Q;2002. Available from:http:\/\/webarchive.nationalarchives.gov.uk\/20160106043431\/http:\/\/www.ons.gov.uk\/ons\/rel\/hsq\/health-statistics-quarterly\/no--13--spring-2002\/index.html[accessed July 2020]."},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2013.03.011"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1532-2149.2014.496.x"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.2217\/pmt.14.26"},{"issue":"43","key":"e_1_2_11_13_1","first-page":"732","article-title":"Long\u2010term opioid use in non\u2010cancer pain","volume":"111","author":"Hauser W","year":"2014","journal-title":"Dtsch Arztebl Int"},{"issue":"3","key":"e_1_2_11_14_1","first-page":"S67","article-title":"American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non\u2010cancer pain: Part 2\u2010\u2010guidance","volume":"15","author":"Manchikanti L","year":"2012","journal-title":"Pain Physician"},{"key":"e_1_2_11_15_1","unstructured":"Public Health England.Opioids Aware: a resource for patients and healthcare professionals to support prescribing of opioid medicines for pain;2016. Available from:https:\/\/www.fpm.ac.uk\/faculty-of-pain-medicine\/opioids-aware[accessed July 2020]."},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2007.03.028"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/AJP.0b013e3181b01710"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa1610524"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2010.273"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-152-2-201001190-00006"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-019-05301-2"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m283"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bja.2019.08.012"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2014.07.006"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1532-2149.2011.00018.x"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2014.03.009"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/aas.12594"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-6576.2012.02766.x"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/aas.12281"},{"issue":"1","key":"e_1_2_11_31_1","first-page":"85","article-title":"Cohort study of the impact of high\u2010dose opioid analgesics on overdose mortality","volume":"17","author":"Dasgupta N","year":"2016","journal-title":"Pain Med"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002396"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2011.117"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j760"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1177\/2042098611435911"},{"key":"e_1_2_11_36_1","unstructured":"Office for National Statistics.Mortality statistics in England and Wales\u2010quality and methodology information;2017. Available from:https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/birthsdeathsandmarriages\/deaths\/qmis\/mortalitystatisticsinenglandandwalesqmi[accessed July 2020]."},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.2307\/2530744"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1093\/biostatistics\/kxr021"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1214\/09-STS313"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000157"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2014.301966"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.370"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269216311398300"},{"key":"e_1_2_11_44_1","unstructured":"World Health Organization.Anatomical therapeutic chemical\/defined daily dose index 2016. March2016. Available from:http:\/\/www.whocc.no\/atc_ddd_index\/[accessed July 2020]."},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a112623"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyt083"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2020.100321"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h2698"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/28.7.616"},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2007.12.003"},{"key":"#cr-split#-e_1_2_11_51_1.1","unstructured":"NHS Scotland.National Therapeutic Indicators 2018.2017"},{"key":"#cr-split#-e_1_2_11_51_1.2","unstructured":"Available from:https:\/\/www.therapeutics.scot.nhs.uk\/wp-content\/uploads\/2018\/08\/National-Therapeutic-Indicators-Report-2018-19-Version-1.0.pdf[accessed July 2020]."},{"key":"e_1_2_11_52_1","unstructured":"NHS Scotland.Quality prescribing for chronic pain \u2013 a guide for improvement 2018\u20102021.2017. Available from:https:\/\/www.therapeutics.scot.nhs.uk\/wp-content\/uploads\/2018\/03\/Strategy-Chronic-Pain-Quality-Prescribing-for-Chronic-Pain-2018.pdf[accessed July 2020]."},{"key":"e_1_2_11_53_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyi060"},{"key":"e_1_2_11_54_1","doi-asserted-by":"publisher","DOI":"10.1590\/1980-5497201500020005"},{"key":"e_1_2_11_55_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a121118"},{"key":"e_1_2_11_56_1","unstructured":"NHS Digital.Quality and Outcomes Framework (QOF) \u2010 2014\u201015.2015. Available from:http:\/\/content.digital.nhs.uk\/catalogue\/PUB18887[accessed June 2016]."}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.15028","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcp.15028","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.15028","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T04:10:45Z","timestamp":1692850245000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.15028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,9]]},"references-count":56,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["10.1111\/bcp.15028"],"URL":"https:\/\/doi.org\/10.1111\/bcp.15028","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,9]]}}}